Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%

Transjugular intrahepatic portosystemic shunts vs Conventional treatment

All‐cause mortality · adults with hepatorenal syndrome

It is very uncertain whether transjugular intrahepatic portosystemic shunts changes all‐cause mortality compared with conventional treatment (very low certainty).

1 finding from 1 review

Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes only
RR 0.88 [0.55, 1.38]
2 studies · 130 participants
Very low

Transjugular intrahepatic portosystemic shunts vs Conventional treatment

All‐cause morbidity · adults with hepatorenal syndrome

Transjugular intrahepatic portosystemic shunts showed no clear difference in morbidity due to any cause compared with conventional treatment (low certainty).

1 finding from 1 review

Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes only
RR 0.95 [0.77, 1.18]
2 studies · 130 participants
Low

Transjugular intrahepatic portosystemic shunts vs Conventional treatment

Serious adverse events · adults with hepatorenal syndrome

It is very uncertain whether transjugular intrahepatic portosystemic shunts changes serious adverse events compared with conventional treatment (very low certainty).

1 finding from 1 review

Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes only
RR 1.6 [0.1, 24.59]
2 studies · 130 participants
Very low

Transjugular intrahepatic portosystemic shunts vs Conventional treatment

Health‐related quality of life · adults with hepatorenal syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Transjugular intrahepatic portosystemic shunts vs Conventional treatment

Participants who did not receive a liver transplant · adults with hepatorenal syndrome

It is very uncertain whether transjugular intrahepatic portosystemic shunts changes participants who did not receive a liver transplant compared with conventional treatment (very low certainty).

1 finding from 1 review

Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes only
RR 1.03 [0.93, 1.14]
2 studies · 130 participants
Very low

Transjugular intrahepatic portosystemic shunts vs Conventional treatment

Participants without improvement in kidney function · adults with hepatorenal syndrome

Transjugular intrahepatic portosystemic shunts showed no clear difference in participants without improvement in kidney function compared with conventional treatment (low certainty).

1 finding from 1 review

Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes only
RR 0.53 [0.27, 1.02]
1 study · 70 participants
Low

Transjugular intrahepatic portosystemic shunts vs Conventional treatment

Length of hospitalisation (days) · adults with hepatorenal syndrome

1 finding from 1 review

Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low